concept

PRMT1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about PRMT1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

417Connections

3Hypotheses

1Analyses

50Outgoing

50Incoming

3Experiments

2Debates

Summary

PRMT1 is a concept in neurodegeneration research. Key relationships include: inhibits, implicated in, regulates. Associated with AD, ALI, ALS. Connected to 112 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	PRMT1
Key Genes/Proteins	Actin, AKT, ALS, AMYOTROPHIC LATERAL SCLEROSIS, AND
Related Diseases	AD, Aging, ALI, Als, AMI
Related Pathways	apoptosis
Linked Hypotheses	2 hypotheses

🔮 Predicted Structure: PRMT1 — AlphaFold A0A3S6H7X9 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Pathway Diagram

graph TD
    PRMT1["PRMT1"]
    PRMT1 -->|"target for"| Cancer["Cancer"]
    PRMT1 -->|"target for"| Cardiovascular["Cardiovascular"]
    PRMT1 -->|"target for"| Ms["Ms"]
    PRMT1 -->|"target for"| Tumor["Tumor"]
    PRMT1 -->|"target for"| Als["Als"]
    PRMT1 -->|"regulates"| Aging["Aging"]
    h_19003961["h-19003961"] -->|"targets"| PRMT1
    FASN["FASN"] -->|"activates"| PRMT1
    KRAS["KRAS"] -->|"inhibits"| PRMT1
    PHGDH["PHGDH"] -->|"activates"| PRMT1
    IDH1["IDH1"] -->|"regulates"| PRMT1
    P38["P38"] -->|"regulates"| PRMT1
    CANCER["CANCER"] -->|"inhibits"| PRMT1
    PRMT5["PRMT5"] -->|"inhibits"| PRMT1
    DNA["DNA"] -->|"regulates"| PRMT1

Outgoing (294)

Target	Relation	Type	Str
Pancreatic Cancer	promotes	disease	0.95
PKM2	associated_with	protein	0.95
De Novo Fatty Acid Synthesis	associated_with	pathway	0.95
DDX1	mediates	protein	0.95
PANCREATIC CANCER	associated_with	entity	0.95
PHGDH	phosphorylates	protein	0.95
SREBF1	interacts_with	gene	0.95
PHGDH	associated_with	gene	0.95
PFKFB3	associated_with	protein	0.95
Pancreatic Ductal Adenocarcinoma	associated_with	disease	0.95
PHGDH enzymatic activity	activates	phenotype	0.94
chemoresistance	drives	phenotype	0.93
SREBF1	phosphorylates	gene	0.90
PARP inhibitor	therapeutic_target	drug	0.90
CANCER	therapeutic_target	entity	0.90
Breast Cancer	therapeutic_target	disease	0.90
Cholangiocarcinoma	contributes_to	disease	0.90
Tumorigenesis	associated_with	process	0.90
Cancer Cell Proliferation	regulates	process	0.90
Cancer Cell Proliferation	activates	process	0.90
TUMORIGENESIS	contributes_to	entity	0.90
CHEMOTHERAPY RESISTANCE	associated_with	entity	0.90
PFKFB3	phosphorylates	entity	0.90
Pancreatic Cancer Development	mediates	process	0.90
Tumorigenesis	mediates	process	0.90
lipid metabolism	regulates	process	0.90
Chemotherapy Resistance	promotes	phenotype	0.90
CELL PROLIFERATION	regulates	entity	0.90
Gastric Cancer	associated_with	disease	0.90
skeletal muscle atrophy	protects_against	disease	0.90
Cancer	targets	disease	0.90
Pancreatic Cancer	expressed_in	disease	0.90
DDX1	phosphorylates	protein	0.90
Cholangiocarcinoma	therapeutic_target	disease	0.90
Fatty Acid Synthesis	associated_with	pathway	0.90
Triple-Negative Breast Cancer	associated_with	disease	0.90
Cancer Development	associated_with	process	0.90
anti-cancer drug resistance	drives	phenotype	0.90
CHEMORESISTANCE	contributes_to	entity	0.90
Chemoresistance	associated_with	phenotype	0.90
p38 mitogen-activated protein kinase	regulates	protein	0.90
PKM2	phosphorylates	entity	0.90
Tacrolimus-Induced Chronic Nephrotoxicity	implicated_in	disease	0.90
Anti-Cancer Drug Resistance	involved_in	phenotype	0.90
Triple-Negative Breast Cancer	therapeutic_target	disease	0.88
CANCER DRUG RESISTANCE	contributes_to	entity	0.85
DNA DAMAGE RESPONSE	regulates	entity	0.85
CELL METABOLISM	regulates	entity	0.85
SPLICING	regulates	entity	0.85
Pancreatic Ductal Adenocarcinoma	therapeutic_target	disease	0.85

Incoming (123)

Source	Relation	Type	Str
Tc-E-5003	inhibits	compound	0.95
Ginger	targets	compound	0.95
exercise preconditioning	upregulates	process	0.90
h-ccc05373	targets_gene	hypothesis	0.90
Gsk715	targets	drug	0.90
h-19003961	targets	hypothesis	0.90
PRMT inhibitors	targets	drug	0.90
Ginsenoside RG3	inhibits	compound	0.85
DDX1	upregulates	protein	0.85
EGR1	activates	gene	0.85
GINGER	inhibits	entity	0.85
EGR1	regulates	entity	0.85
Cantharidin	inhibits	drug	0.80
USP10	associated_with	protein	0.80
FUS	associated_with	gene	0.70
FUS	accumulates_in	gene	0.70
Ginger Active Ingredients	binds	compound	0.70
ALS	accumulates_in	gene	0.70
Ginger Active Ingredients	inhibits	compound	0.70
AND	regulates	gene	0.60
FTLD	associated_with	gene	0.60
ALS	interacts_with	gene	0.60
PKM2	associated_with	gene	0.60
NEUROTOXICITY	inhibits	gene	0.60
AMYOTROPHIC LATERAL SCLEROSIS	inhibits	gene	0.60
MOTOR NEURONS	inhibits	gene	0.60
glycolysis	activates	pathway	0.60
PFKM	activates	gene	0.60
KRAS	inhibits	gene	0.60
CANCER	inhibits	gene	0.60
MITOPHAGY	activates	gene	0.60
PFKFB3	activates	gene	0.60
PFKFB3	therapeutic_target	gene	0.60
DNA	therapeutic_target	gene	0.60
RNA	therapeutic_target	gene	0.60
AUTOPHAGY	therapeutic_target	gene	0.60
KRAS	associated_with	gene	0.60
metformin	targets	drug	0.60
CANCER	regulates	entity	0.60
FASN	activates	gene	0.60
IDH1	regulates	gene	0.60
P38	regulates	gene	0.60
PINK1	activates	gene	0.60
PRMT5	therapeutic_target	gene	0.60
OVERVIEW	expressed_in	gene	0.60
AKT	inhibits	gene	0.60
PI3K	inhibits	gene	0.60
AKT	regulates	gene	0.60
PI3K	regulates	gene	0.60
FUS	interacts_with	gene	0.60

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
p38α Inhibitor and PRMT1 Activator Combination to Restore Ph	0.848	neurodegeneration	What is the therapeutic window between i
Arginine Methylation Enhancement Therapy	0.653	neurodegeneration	TDP-43 phase separation therapeutics for
Small-Molecule Modulation of G3BP1 Condensate Dynamics via P	0.400	neurodegeneration	How do disease-associated mutations in G

Mentioning Analyses (1)

Scientific analyses that reference this entity

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.738

Experiments (3)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
Network pharmacology screening of ginger targets against gastric cance	exploratory	gastric cancer	0.900	computational analysis using h	proposed	N/A
MAPK pathway inhibition by QTJD through butyrate mechanism	exploratory	Mycoplasma pneumoniae pneumoni	0.900	Mouse macrophages	proposed	N/A
Molecular docking validation of ginger-PRMT1 interactions	exploratory	gastric cancer	0.800	computational molecular dockin	proposed	N/A

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Predicting the molecular mechanism of ginger targeting PRMT1/BTG2 axis to inhibi [PMID:40446574]	Chen G, Gou B, Du Y, Zhou Z, Bai Y, Yang	Phytomedicine	2025	1
PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. [PMID:38460517]	Ku B, Eisenbarth D, Baek S, Jeong TK, Ka	Cell Rep Med	2024	1
PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemor [PMID:38383964]	Yamamoto T, Hayashida T, Masugi Y, Oshik	Cancer Res	2024	1
Promising role of protein arginine methyltransferases in overcoming anti-cancer [PMID:37980859]	Zhu Y, Xia T, Chen DQ, Xiong X, Shi L, Z	Drug Resist Updat	2024	1
Protein arginine methylation: from enigmatic functions to therapeutic targeting. [PMID:33742187]	Wu Q, Schapira M, Arrowsmith CH, Barsyte	Nat Rev Drug Discov	2021	1
Repression of PRMT activities sensitize human homologous recombination-proficien [PMID:41632514]	["Zhang Y", "Xu M", "Yuan J", "Hu Z", "J	eLife	2026	0
Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepa [PMID:41501793]	["Wang Y", "Yuan H", "Yu Y", "Gou X", "W	Journal of translational medic	2026	0
Protein arginine methyltransferases in cancer: mechanisms, functions, and therap [PMID:41928257]	Jeong Y, Cho Y, Kim YK	J Biomed Sci	2026	0
Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, [PMID:41801765]	Thiebaut C, Martinez S, Pruvost L, Eve L	Cancer science	2026	0
Potentiating BSEP-mediated bile acid efflux reverses first-line tyrosine kinase [PMID:41903671]	Wu Z, Wang Y, Yu B, Yu R, Chen M, Chen Z	Cancer letters	2026	0
LC-MS profiling of [PMID:41756837]	["Basirattalab A", "Wallis D", "Hartel N	bioRxiv : the preprint server	2026	0
Discovery of the First-in-Class Protein Arginine Methyltransferase 1 PROTAC Degr [PMID:41830641]	Guo S, Li J, Lin J, Chen Y, Liu C, Liu H	Journal of medicinal chemistry	2026	0
PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulatin [PMID:41912914]	Tian Z, Gao P, Zhang Y, Ma J, Hu X, Wang	Leukemia	2026	0
PFKM governs metabolic shifts throughout skeletal muscle differentiation. [PMID:41735679]	["Campos M", "Nguyen S", "Kong X", "Yang	Nature metabolism	2026	0
PRMT1-rich exosomes derived from M2 macrophages as novel therapeutics for enhanc [PMID:41610641]	["Hong H", "Zhou C", "Wang H", "Lin C",	Tissue & cell	2026	0
Exercise preconditioning prevents immobilization-induced skeletal muscle atrophy [PMID:41737591]	["Yang X", "Zou Y", "Wang H", "Niu Y", "	Sports medicine and health sci	2026	0
Arginine methylation-dependent stabilization of SUV39H1 promotes breast cancer g [PMID:41795022]	Zhao W, Wang G, Wang P, Ma B, Liu B, Fu	Oncogene	2026	0
PRMT1-mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes [PMID:41668296]	["Liu W", "Liao Y", "Kuai Y", "Gao X", "	Clinical and molecular hepatol	2026	0
Trans-Omic Analysis Identifies the 'PRMT1-STAT3-Integrin αVβ6 Axis' as a Novel T [PMID:41226322]	["Nishida S", "Ishima T", "Iwami D", "Na	International journal of molec	2025	0
Metformin suppresses gastric cancer progression by disrupting the STAT1-PRMT1 ax [PMID:38876258]	["Wang K", "Chen Y", "Zhang M", "Wang S"	Biochemical pharmacology	2024	0

Debates (2)

Multi-agent debates referencing this entity

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

closed · Rounds: 6 · Score: 0.84 · 2026-04-12

TDP-43 phase separation therapeutics for ALS-FTD

closed · Rounds: 4 · Score: 0.95 · 2026-04-11

Related Research

Hypotheses and analyses mentioning PRMT1 in their description or question text

No additional research found